Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Li, Yaru ^a   Wang, Jing ^a   Tang, Yuhan ^a   Han, Xu ^a   Liu, Bing ^a   Hu, Hua ^a   Li, Xiulou ^b   Yang, Kun ^b   Yuan, Jing ^a   Miao, Xiaoping ^a   Yao, Ping ^a   Wei, Sheng ^a   Wang, Youjie ^a   Liang, Yuan ^a   Zhang, Xiaomin ^a   Guo, Huan ^a   Pan, An ^a   Yang, Handong ^b   Hu, Frank B ^c   Wu, Tangchun ^a   He, Meian ^a   more..

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ADULT; AGE; ARTICLE; CHINESE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; RISK ASSESSMENT; RISK FACTOR; AGED; ANALYSIS; BLOOD; CHINA; COMPLICATION; EPIDEMIOLOGY; INCIDENCE; PROPORTIONAL HAZARDS MODEL;

AGED; BLOOD GLUCOSE; CHINA; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROPORTIONAL HAZARDS MODELS;

EID: 85016257496     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0174291     Document Type: Article

References (44)

1. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310: 948-959. https://doi.org/10.1001/jama.2013.168118 PMID: 24002281
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142: 1592-1609. https://doi.org/10.1053/j.gastro.2012.04.001 PMID: 22656328
3. Fan J-G, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009; 50: 204-210. https://doi.org/10.1016/j.jhep.2008.10.010 PMID: 19014878
4. López-Velázquez JA, Silva-Vidal KV, Ponciano-Rodríguez G, Chávez-Tapia NC, Arrese M, Uribe M, et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol. 2014; 13: 166-178. PMID: 24552858
5. Li Z, Xue J, Chen P, Chen L, Yan S, Liu L. Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies. J Gastroenterol Hepatol. 2014; 29: 42-51. https://doi.org/10.1111/jgh.12428 PMID: 24219010
6. Williams K, Shackel N, Gorrell M, McLennan S, Twigg S. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev. 2012; 34: 84-129. https://doi.org/10.1210/er.2012-1009 PMID: 23238855
7. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016; 31: 936-944. https://doi.org/10.1111/jgh.13264 PMID: 26667191
8. Fukuda T, Hamaguchi M. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int. 2016; 36: 275-283. https://doi.org/10.1111/liv.12912 PMID: 26176710
9. Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes. Diabetes Care. 2015; 38: 1673-1679. https://doi.org/10.2337/dc15-0140 PMID: 26156527
10. Fukuda T, Hamaguchi M, Kojima T, Mitsuhashi K, Hashimoto Y, Ohbora A, et al. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men. Eur J Gastroenterol Hepatol. 2016; 28: 1443-1449. https://doi.org/10.1097/MEG.0000000000000736 PMID: 27603300
11. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009; 29: 113-119. https://doi.org/10.1111/j.1478-3231.2008.01718.x PMID: 18384521
12. Porepa L, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ. 2010; 182: E526-531. https://doi.org/10.1503/cmaj.092144 PMID: 20566726
13. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res. 2013; 43: 51-64. https://doi.org/10.1111/j.1872-034X.2012.01031.x PMID: 23332087
14. Valenti L, Bugianesi E, Pajvani U, Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int. 2016; 36: 1563-1579. https://doi.org/10.1111/liv.13185 PMID: 27276701
15. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014; 2: 901-910. https://doi.org/10.1016/S2213-8587(14)70032-4 PMID: 24731669
16. Zhang Y, Zhang T, Zhang C, Tang F, Zhong N, Li H, et al. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open. 2015; 5: e008204. https://doi.org/10.1136/bmjopen-2015-008204 PMID: 26395497
17. Reynolds K, Gu D, Whelton PK, Wu X, Duan X, Mo J, et al. Prevalence and risk factors of overweight and obesity in China. Obesity. 2007; 15: 10-18. https://doi.org/10.1038/oby.2007.527 PMID: 17228026
18. Zhou BF. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults-study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002; 15: 83-96. PMID: 12046553
19. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123: 745-750. PMID: 12198701
20. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease. J Dig Dis. 2011; 12: 38-44. https://doi.org/10.1111/j.1751-2980.2010. 00476.x PMID: 21276207
21. Standards of medical care in diabetes-2012. Diabetes Care. 2012; 35 Suppl 1: S11-63.
22. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO. 2006.
23. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008; 25: 476-481. https://doi.org/10.1111/j.1464-5491.2008.02410.x PMID: 18346164
24. Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013; 57: 1378-1383. https://doi.org/10.1002/hep.26183 PMID: 23213066
25. Lee IT, Chiu YF, Hwu CM, He CT, Chiang FT, Lin YC, et al. Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study. Cardiovasc Diabetol. 2012; 11: 43. https://doi.org/10.1186/1475-2840-11-43 PMID: 22537054
26. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004; 279: 32345-32353. https://doi.org/10.1074/jbc. M313478200 PMID: 15166226
27. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes care. 2012; 35: 873-878. https://doi.org/10.2337/dc11-1849 PMID: 22374640
28. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120: 1183-1192. https://doi.org/10.1053/gast.2001.23256 PMID: 11266382
29. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes the atherosclerosis risk in communities study. Diabetes. 2003; 52: 1799-1805. PMID: 12829649
30. Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014; 49: 1477-1484. https://doi.org/10.1007/s00535-013-0911-1 PMID: 24277052
31. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126: 460-468. PMID: 14762783
32. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med. 2006; 166: 106-111. https://doi.org/10.1001/archinte.166.1.106 PMID: 16401818
33. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015; 62: S47-64. https://doi.org/10.1016/j.jhep.2014.12.012 PMID: 25920090
34. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013; 98: 3637-3643. https://doi.org/10.1210/jc.2013-1519 PMID: 23873989
35. Targher G, Marchesini G, Byrne CD. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? Diabetes Metab. 2016; 42: 142-156. https://doi.org/10.1016/j.diabet.2016.04.002 PMID: 27142870
36. Zhang T, Zhang C, Zhang Y, Tang F, Li H, Zhang Q, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis. 2015; 240: 144-148. https://doi.org/10.1016/j.atherosclerosis.2015.02. 049 PMID: 25785362
37. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015; 47: 997-1006. https://doi.org/10.1016/j.dld.2015.08.004 PMID: 26454786
38. Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016; 46: 1074-1087. https://doi.org/10.1111/hepr.12656 PMID: 26785389
39. Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient-death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol. 2011; 5: 279-289. https://doi.org/10.1586/egh.11.19 PMID: 21476922
40. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011; 7: 456-465. https://doi.org/10.1038/nrendo.2011.72 PMID: 21556019
41. Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013; 34: 84-129. https://doi.org/10.1210/er.2012-1009 PMID: 23238855
42. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221-1231. https://doi.org/10.1056/NEJMra011775 PMID: 11961152
43. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011; 54: 1082-1090. https://doi.org/10.1002/hep.24452 PMID: 21618575
44. Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol. 2015; 9: 603-627. https://doi.org/10.1586/17474124.2015.1007955 PMID: 25694178